 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 July 1995 | Volume 123 Issue 2 | Pages 132-142
Purpose: To assess the effectiveness of azathioprine and 6-mercaptopurine in inducing remission of active Crohn disease and the effectiveness of azathioprine in maintaining remission of quiescent disease.
Data Sources: Pertinent studies were selected from the MEDLINE database (1966 to May 1994), abstracts from major gastrointestinal meetings, and references from published articles and reviews.
Study Selection: Nine randomized, placebo-controlled trials of azathioprine or 6-mercaptopurine therapy were identified: Four addressed active disease, two addressed quiescent disease, and three had multiple therapeutic arms.
Data Extraction: Data were extracted by three independent observers on the basis of the intention-to-treat principle and were analyzed with logistic regression. Each study was given a quality score on the basis of predetermined criteria.
Data Synthesis: Compared with placebo, azathioprine or 6-mercaptopurine therapy had an odds ratio of response of 3.09 (95% CI, 2.45 to 3.91) in patients with active Crohn disease. When the single trial that used 6-mercaptopurine in active disease was excluded from the analysis, the odds ratio of response was 1.45 (CI, 1.12 to 1.87). No trials of quiescent disease used 6-mercaptopurine; the odds ratio of response in these trials of quiescent disease was 2.27 (CI, 1.76 to 2.93). For active disease, continuation of therapy for at least 17 weeks improved response (P = 0.03). For quiescent disease, a higher dose improved response (P = 0.008). Increased cumulative dose improved response in both groups (P < 0.001 for active disease and P = 0.01 for quiescent disease). A steroid-sparing effect was seen in active disease (odds ratio, 3.69 [CI, 2.12 to 6.42] and in quiescent disease (odds ratio, 4.64 [CI, 1.00 to 21.54]). Fistulae improved with therapy (odds ratio, 4.44 [CI, 1.50 to 13.20]). Adverse events requiring withdrawal from a trial, primarily allergy, leukopenia, pancreatitis, and nausea, were increased with therapy (odds ratio, 5.26 [CI, 2.20 to 12.60]).
Conclusions: Azathioprine and 6-mercaptopurine are effective in treating active Crohn disease and in maintaining remission. Cumulative dose was an important factor in predicting response. Adverse effects were more common among patients receiving therapy.
Author and Article Information
From the University of Calgary, Calgary, Alberta, Canada.
REVIEW
Azathioprine and 6-Mercaptopurine in Crohn Disease
A Meta-Analysis
Requests for Reprints: Lloyd Sutherland, MD, Room 1751, Health Sciences Centre, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1 Canada.
Grant Support: Dr. Pearson is a Glaxo Canada research fellow.
This article has been cited by other articles:
|
|
 |
|
  M. Reinshagen, E. Schutz, V. W. Armstrong, C. Behrens, C. von Tirpitz, A. Stallmach, H. Herfarth, J. Stein, P. Bias, G. Adler, et al. 6-Thioguanine Nucleotide-Adapted Azathioprine Therapy Does Not Lead to Higher Remission Rates Than Standard Therapy in Chronic Active Crohn Disease: Results from a Randomized, Controlled, Open Trial Clin. Chem., July 1, 2007; 53(7): 1306 - 1314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U Hindorf, M Lindqvist, C Peterson, P Soderkvist, M Strom, H Hjortswang, A Pousette, and S Almer Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease Gut, October 1, 2006; 55(10): 1423 - 1431. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Gardiner and E. J. Begg Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice Pharmacol. Rev., September 1, 2006; 58(3): 521 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S P L Travis, E F Stange, M Lemann, T Oresland, Y Chowers, A Forbes, G D'Haens, G Kitis, A Cortot, C Prantera, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management Gut, March 1, 2006; 55(suppl_1): i16 - i35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. von Ahsen, V. W. Armstrong, C. Behrens, C. von Tirpitz, A. Stallmach, H. Herfarth, J. Stein, P. Bias, G. Adler, M. Shipkova, et al. Association of Inosine Triphosphatase 94C>A and Thiopurine S-Methyltransferase Deficiency with Adverse Events and Study Drop-Outs under Azathioprine Therapy in a Prospective Crohn Disease Study Clin. Chem., December 1, 2005; 51(12): 2282 - 2288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Cosnes, I Nion-Larmurier, L Beaugerie, P Afchain, E Tiret, and J-P Gendre Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery Gut, February 1, 2005; 54(2): 237 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. W. Thomas, G. M. Myhre, R. Tschumper, R. Sreekumar, D. Jelinek, D. J. McKean, J. J. Lipsky, W. J. Sandborn, and L. J. Egan Selective Inhibition of Inflammatory Gene Expression in Activated T Lymphocytes: A Mechanism of Immune Suppression by Thiopurines J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 537 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. E. Sands, F. H. Anderson, C. N. Bernstein, W. Y. Chey, B. G. Feagan, R. N. Fedorak, M. A. Kamm, J. R. Korzenik, B. A. Lashner, J. E. Onken, et al. Infliximab Maintenance Therapy for Fistulizing Crohn's Disease N. Engl. J. Med., February 26, 2004; 350(9): 876 - 885. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-T. Oh, A. H. Anis, and S.-C. Bae Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea Rheumatology, February 1, 2004; 43(2): 156 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A G Fraser, T R Orchard, and D P Jewell The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review Gut, April 1, 2002; 50(4): 485 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W J SANDBORN Rational dosing of azathioprine and 6-mercaptopurine Gut, May 1, 2001; 48(5): 591 - 592. [Full Text] [PDF]
|
|
|
|
|
|
S G NUGENT, D KUMAR, D S RAMPTON, and D F EVANS Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs Gut, April 1, 2001; 48(4): 571 - 577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Hart Moderate to Severe Crohn's Disease: 6-Mercaptopurine New First Line Therapy AAP Grand Rounds, March 1, 2001; 5(3): 21 - 22. [Full Text] [PDF]
|
|
|
|
 |
|
 E. THERVET, D. ANGLICHEAU, N. TOLEDANO, A.-M. HOULLIER, L.-H. NOEL, H. KREIS, P. BEAUNE, and C. LEGENDRE Long-Term Results of TPMT Activity Monitoring in Azathioprine-Treated Renal Allograft Recipients J. Am. Soc. Nephrol., January 1, 2001; 12(1): 170 - 176. [Abstract] [Full Text]
|
|
|
|
 |
|
 P A Brogan and M J Dillon Personal practice: The use of immunosuppressive and cytotoxic drugs in non-malignant disease Arch. Dis. Child., September 1, 2000; 83(3): 259 - 264. [Full Text] [PDF]
|
|
|
|
|
|
D. H. Present, P. Rutgeerts, S. Targan, S. B. Hanauer, L. Mayer, R.A. van Hogezand, D. K. Podolsky, B. E. Sands, T. Braakman, K. L. DeWoody, et al. Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease N. Engl. J. Med., May 6, 1999; 340(18): 1398 - 1405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L R SUTHERLAND and A H STEINHART Mesalazine as a maintenance treatment in Crohn's disease Gut, January 1, 1998; 42(1): 143b - 143. [Full Text]
|
|
|
|
|
|
S. B. Hanauer Inflammatory Bowel Disease N. Engl. J. Med., March 28, 1996; 334(13): 841 - 848. [Full Text] [PDF]
|
|
Article
